Duhao Net helps individual entrepreneurs and enterprises find high-quality suppliers, reduce procurement costs, and make transactions easier.
Release time：2024-07-06 22:01:13 Source：Duhao
Semaglutide is a medication that belongs to a class of drugs known as GLP-1 receptor agonists. It mimics the effects of a natural hormone called glucagon-like peptide-1 (GLP-1), stimulating the pancreas to produce insulin and reducing the hunger hormone ghrelin. This helps to decrease appetite, slow down stomach emptying, lower blood sugar levels, and promote weight loss. It is commonly administered as a weekly subcutaneous injection.
Uses: From Type 2 Diabetes Treatment to Weight Loss
Type 2 Diabetes Treatment: Initially approved for managing type 2 diabetes, it helps in lowering blood glucose levels.
Weight Management: Recognized for its weight loss effects, it is used for managing obesity, especially in overweight patients.
Cardiovascular Risk Reduction: Studies have shown that semaglutide can reduce the risk of major cardiovascular events in adults with type 2 diabetes and those with existing cardiovascular diseases.
Latest Research:
Kidney Protection: Studies suggest that semaglutide may offer protection to kidney health and reduce the risk of chronic kidney disease.
Reduced Risk of Colorectal Cancer: Research indicates that patients with type 2 diabetes using semaglutide have a lower incidence of colorectal cancer.
Reduced Risk of Dementia: Studies propose that type 2 diabetic patients using GLP-1 receptor agonists like semaglutide may have a lower rate of dementia compared to those given a placebo.
Reduced Risk of Acute Pancreatitis: Research has shown that semaglutide may decrease the risk of acute pancreatitis.
Symptom Reduction in Substance Addiction: Small studies suggest that semaglutide may alleviate symptoms of alcohol use disorder.
Polycystic Ovary Syndrome (PCOS) Treatment: Anecdotal evidence and small studies hint that semaglutide may help treat symptoms of PCOS.
Link to Vision Loss: Studies have found an association between the use of semaglutide and an increased risk of a rare condition called nonarteritic anterior ischemic optic neuropathy (NAION), which can lead to vision loss.
Reduced Cancer Risk: Research points to a reduced risk of certain obesity-associated cancers in type 2 diabetic patients using semaglutide.
SELECT Trial: This trial examined the effects of semaglutide on weight and anthropometric outcomes, safety, and tolerability in overweight or obese adults without diabetes, showing significant and sustained weight loss over 4 years.
Risk warning
At the 18th Oriental Cardiology Conference (OCC 2024) and the World Congress of Cardiology (WCC 2024), Professor Daniel Piñeiro, President of the World Heart Federation (WHF), pointed out that although GLP-1 drugs such as semaglutide are effective in treating obesity, they are not the fundamental means to solve the global obesity problem. The real key lies in changing lifestyle. This view emphasizes the association between obesity and a variety of serious diseases such as heart disease, diabetes, and kidney disease, and points out that obesity is rising rapidly worldwide, especially among children. Piñeiro said that the global challenge of obesity cannot be solved by drugs alone, but needs to be addressed through lifestyle changes and comprehensive preventive measures. At the same time, a study from Harvard Medical School revealed that semaglutide may increase the risk of non-arteritic anterior ischemic optic neuropathy (NAION), which has attracted widespread attention from the medical and investment communities. The research team found that the diagnosis rate of NAION in diabetic patients using the drug was significantly higher than that of non-users. Although semaglutide has brought significant weight loss effects, its potential eye risks require careful consideration in clinical use. At the same time, Novo Nordisk said it would limit sales of its blockbuster weight loss drug Novavax in China to ensure a balanced global drug supply.